# Dr Lal PathLabs Acquires SN Genelab Stake

> Dr Lal PathLabs to buy 70% stake in SN Genelab for Rs 168 crore.
- Title: Dr Lal PathLabs Acquires SN Genelab Stake · The Economic Times
- Summary: Dr Lal PathLabs to buy 70% stake in SN Genelab for Rs 168 crore. Dr Lal PathLabs acquires 70% stake in SN Genelab for Rs 168 crore to boost genomic…
- Keywords: dr lal pathlabs, sn genelab, genomic diagnostic services, acquisition, stake purchase, biotech, Lal, PathLabs, Acquires, Genelab, Stake, The Economic Times
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/dr-lal-pathlabs-to-acquire-70-pc-stake-in-sn-genelab-for-rs-168-crore/articleshow/134465323.cms
- Author: PTI
- Published: 2026-09-24T14:59:00+00:00
- Read time: 1 min
- Topics: dr lal pathlabs, sn genelab, genomic diagnostic services, acquisition, stake purchase, biotech
## Dr Lal PathLabs Announces Stake Acquisition
Dr Lal PathLabs Ltd said its board approved a 70 per cent stake acquisition in Gujarat-based SN Genelab for about Rs 168 crore.
## Transaction Includes Performance Earn-Out
The deal features a performance-linked earn-out capped at Rs 31.5 crore, as per the regulatory filing.
## SN Genelab Becomes Subsidiary
Following the acquisition, SN Genelab will become a subsidiary of Dr Lal PathLabs.
## Dr Lal PathLabs Goals for Genomics
Dr Lal PathLabs aims to strengthen its genomics expertise and broaden advanced diagnostic services portfolio.
## Transaction Completion Deadline
The transaction is expected to be completed by November 30, 2026, according to the filing.
## SN Genelab Financial Performance
SN Genelab reported turnover of Rs 57.96 crore in FY26 versus Rs 53.36 crore in FY25 and Rs 43.27 crore in FY24.
## Key takeaway

Dr Lal PathLabs acquires 70% stake in SN Genelab for Rs 168 crore to boost genomic diagnostic services.